Graz Critical Limb Ischemia Score: A Risk Score for Critical Limb Ischemia in Peripheral Arterial Occlusive Disease

Thomas Gary, MD, Klara Belaj, MD, Franz Hafner, MD, Philipp Eller, MD, Peter Rief, MD, Gerald Hackl, MD, and Marianne Brodmann, MD

Abstract: Critical limb ischemia (CLI), a frequently encountered disorder, is associated with a high rate of limb amputation and mortality. To identify patients at high risk for CLI, we developed a simple risk score for peripheral arterial occlusive disease (PAOD).

In our cross-sectional study, we first evaluated 1000 consecutive PAOD patients treated at our institution from 2005 to 2007, documenting clinical symptoms, comorbidities, and concomitant medication. We calculated odds ratios (OR) in a binary logistic regression model to find possible risk factors for CLI. We then verified the score in a second step that included the 1124 PAOD patients we treated between 2007 and 2011.

In the first patient group, the greatest risk factors for CLI were age ≥75 years (OR 2.0), type 2 diabetes (OR 3.1), prior myocardial infarction (OR 2.5), and therapy with low molecular weight heparin (OR 2.8). We scored 1 point for each of those conditions. One point was given for age between 65 and 75 years (OR 1.6) as well as for therapy with cardiac glycosides (OR 1.9) or loop diuretic therapy (OR 1.5). As statin therapy was protective for CLI with an OR of 0.5, we subtracted 1 point for those patients.

In the second group, we could prove that frequency of CLI was significantly higher in patients with a high CLI score. The score correlated significantly with inflammatory parameters (eg, c-reactive protein and fibrinogen). We were also able to define 3 different risk groups for low (score 1–2), intermediate (score 2–4), and high CLI risk (score >4).

We developed a simple risk stratification scheme that is based on conditions that can be easily assessed from the medical history, without any laboratory parameters. This score should help to identify PAOD patients at high risk for CLI.

METHODS

For our cross-sectional study, we formed a first cohort of 1000 patients with PAOD treated at our department between 2003 and 2007 to identify CLI risk factors and to develop our scoring model. We validated our scoring system with a second cohort, consisting of 1124 PAOD patients we treated between 2007 and 2011.

The inclusion criterion for our study was treatment at our institution for PAOD during the given time period; there were no exclusion criteria. The study was approved by the Institutional Review Board of the Medical University of Graz, Austria (IRB Number 24-506 ex 11/12). As this was a retrospective analysis of blinded data, the Board agreed that neither written nor verbal consent would be required.

PAOD was diagnosed and graded in our outpatient clinic on the basis of clinical evaluation, ankle brachial index, and duplex scan according to the TASC II criteria. Successive PAOD patients presenting at our outpatient angiology clinic were scheduled for admission to our ward for further treatment of their atherosclerotic disease. PAOD was graded according to the Fontaine classification. CLI was defined as PAOD presenting with ischemic rest pain and/or skin ulceration/gangrene in accordance with current guidelines and corresponding to Fontaine classes 3 and 4. Upon hospital admission, the patient’s medical records were analyzed systematically for cardiovascular risk factors, comorbidities, and medication. Clinical symptoms were evaluated with a physical examination. Fasting blood samples were taken for laboratory studies.

Statistical Analyses

The subjects’ clinical characteristics were analyzed with descriptive statistics. Groups were compared with the χ² test for
RESULTS

The patients’ characteristics are shown in Table 1. There were statistically significant differences between cohort 1 and cohort 2 with respect to the incidence of coronary artery disease (CAD; 326 [32.6%] vs 420 [37.4%], P < 0.03) and atrial fibrillation (149 [14.9%] vs 219 [19.4%, P = 0.01]). With regard to concomitant medication we found differences in antplatelet therapy (aspirin: 414 [41.4%] vs 379 [33.7%, P = 0.001] and clopidogrel (152 [15.2%] vs 287 [25.5%, P = 0.001]). This might be because of the differences in the time periods when patients presented at our outpatient clinic, where cohort 1 was treated between 2004 and 2007 and cohort 2 between 2007 and 2011. During the latter period, patients were increasingly treated with clopidogrel. Furthermore, CAD frequency differed significantly between groups also leading to a difference in concomitant medication (angiotensin receptor blocker and β-blocker: 112 [11.2%] vs 171 [15.2%], P = 0.01, and 381 [38.1%] vs 495 [44%], P = 0.01).

Parameters of medical history and concomitant medication were first evaluated in a univariate regression analysis for the occurrence of CLI in cohort 1 (Table 2). Variables exhibiting a significance level of P < 0.05 on univariate analysis were then entered into a multivariate binary logistic regression model. In cohort 1, the strongest risk factors for CLI in the multivariate regression model were age > 75 years (OR 2.0 [95% confidence interval [CI] 1.3–3.0], P < 0.001), type 2 diabetes (OR 3.1 [95% CI 2.2–4.4], P < 0.001), prior MI (OR 2.5 [95% CI 1.1–5.5], P = 0.03), and therapy with low molecular weight heparin (LMWH) (2.8 [95% CI 1.7–4.4], P < 0.001). For those conditions we scored 2 points each. One point was given for age between 65 and 75 years (OR 1.6 [95% CI 1.1–2.5], P < 0.03) as well as for use of cardiac glycosides (OR 1.9 [95% CI 1.3–3.4], P = 0.003) or loop diuretics (OR 1.5 [95% CI 1.1–2.1], P = 0.01). As statin therapy was associated with an OR of 0.5 (95% CI 0.4–0.8, P < 0.001), we subtracted 1 point for those patients (Table 3).

In the second group of patients, we could prove that the frequency of CLI was significantly higher in patients with a high CLI score (Table 4). The high-risk group (score 6–10) was

| TABLE 1. Patients’ Characteristics of Peripheral Arterial Occlusive Disease Patients Included in the Study (Cohort 1 and Cohort 2) |
| --- |
| **Cohort 1 (n = 1000)** | **Cohort 2 (n = 1124)** | **P** |
| Age, y, median (25th–75th percentile) | 68.8 (58.9–78.1) | 69.1 (60.0–77.3) | 0.3 |
| Men, n (%) | 590 (59) | 674 (60) | 0.8 |
| BMI, kg/m², median (25th–75th percentile) | 26 (24–29) | 26 (23–28) | 0.9 |
| CRP, mg/L, median (25th–75th percentile) | 6.4 (3.0–10.4) | 6.2 (2.9–10.0) | 0.5 |
| Fibrinogen, mg/dL, median (25th–75th percentile) | 410 (340–520) | 405 (330–510) | 0.7 |
| Concomitant disease | | | |
| Hypertension, n (%) | 780 (78) | 906 (80.6) | 0.4 |
| Type 2 diabetes, n (%) | 343 (34.3) | 370 (32.9) | 0.5 |
| Stroke/TIA, n (%) | 57 (5.7) | 77 (6.8) | 0.3 |
| CAD, n (%) | 326 (32.6) | 420 (37.4) | 0.03 |
| CLI, n (%) | 322 (32.2) | 315 (28.0) | 0.1 |
| Prior myocardial infarction, n (%) | 36 (3.6) | 56 (4.9) | 0.1 |
| Atrial fibrillation, n (%) | 149 (14.9) | 219 (19.4) | 0.01 |
| Concomitant medication | | | |
| Cardiac glycosides, n (%) | 106 (10.6) | 109 (9.7) | 0.5 |
| Statins, n (%) | 563 (56.3) | 589 (52.4) | 0.2 |
| Loop diuretics, n (%) | 412 (41.2) | 508 (45.2) | 0.07 |
| LMWH, n (%) | 109 (10.9) | 90 (8.0) | 0.1 |
| VKA, n (%) | 200 (20) | 204 (18.1) | 0.3 |
| Aspirin, n (%) | 414 (41.4) | 379 (33.7) | 0.001 |
| Clopidogrel, n (%) | 152 (15.2) | 287 (25.5) | 0.001 |
| Insulin, n (%) | 158 (15.8) | 198 (17.6) | 0.1 |
| ACE inhibitors, n (%) | 445 (44.5) | 528 (46.9) | 0.3 |
| Angiotensin receptor blocker, n (%) | 112 (11.2) | 171 (15.2) | 0.01 |
| β-blocking drugs, n (%) | 381 (38.1) | 495 (44) | 0.01 |
| Calcium channel blockers, n (%) | 233 (23.3) | 295 (26.2) | 0.1 |
| Aldosteron antagonists, n (%) | 48 (4.8) | 71 (6.3) | 0.2 |
| Oral antidiabetic drugs, n (%) | 129 (12.9) | 154 (13.7) | 0.6 |

ACE = angiotensin-converting enzyme, BMI = body mass index, CAD = coronary artery disease, CLI = critical limb ischemia, CRP = C-reactive protein, LMWH = low molecular weight heparin, TIA = transient ischemic attack, VKA = vitamin K antagonist.
TABLE 2. Risk Factors for Critical Limb Ischemia in Peripheral Arterial Occlusive Disease Patients (Cohort 1) in Univariate Regression Analysis

| Risk Factor                                      | OR (95% CI)   | P     |
|-------------------------------------------------|---------------|-------|
| Age ≥ 75 y                                      | 2.8 (2.4–3.2) | <0.001|
| Age 65–74 y                                     | 2.0 (1.5–2.5) | 0.01  |
| Type 2 diabetes                                 | 3.9 (3.6–4.2) | <0.001|
| Smoking                                         | 0.9 (0.6–1.2) | 0.8   |
| Heart failure                                   | 1.3 (0.9–1.7) | 0.2   |
| TIA                                            | 1.2 (0.8–1.6) | 0.5   |
| Hypertension                                    | 0.8 (0.5–1.1) | 0.7   |
| CAD                                            | 1.3 (0.9–1.7) | 0.7   |
| Prior myocardial infarction                     | 2.8 (2.4–3.2) | <0.001|
| Atrial fibrillation                             | 1.5 (0.9–2.1) | 0.08  |
| Concomitant medication                          |               |       |
| ACE inhibitors                                  | 1.4 (0.8–2.0) | 0.09  |
| β-blockers                                      | 0.9 (0.6–1.2) | 0.6   |
| Cardiac glycosides                              | 2.4 (1.4–3.4) | 0.003 |
| Calcium channel blockers                        | 1.4 (0.9–1.9) | 0.1   |
| Loop diuretics                                  | 1.8 (1.1–2.5) | 0.01  |
| LMWH                                           | 3.0 (1.9–4.1) | <0.001|
| VKA                                            | 1.4 (0.9–1.9) | 0.07  |
| Aspirin                                         | 1.2 (0.9–1.5) | 0.1   |
| Clopidogrel                                     | 1.4 (0.9–1.9) | 0.1   |
| Oral anti diabetic drugs                        | 1.2 (0.8–1.6) | 0.09  |
| Insulin                                         | 1.3 (0.9–1.7) | 0.2   |
| Statins                                         | 0.4 (0.2–0.6) | <0.001|

ACE = angiotensin-converting enzyme, CAD = coronary artery disease, LMWH = low molecular weight heparin, OR = odds ratio, TIA = transient ischemic attack, VKA = vitamin K antagonist.

very small and we actually were not able to show a linear progression for CLI in these patients, but we nonetheless were able to define 3 different risk groups (low CLI risk: score – 1 to 1, n = 434; intermediate CLI risk: score 2–4, n = 569; and high CLI risk: score 5–10, n = 121) according to the number of score points (Table 1). The CLI rate was significantly higher in patients with a higher score, especially those with a score of >4 points (Figure 1). The statistical trend we saw for the increase in the CLI rate with increasing score points was statistically significant (P < 0.001).

We analyzed the correlation of the Graz CLI score with the inflammatory parameters that reflect the activity of the underlying atherosclerotic disease. We calculated Pearson’s correlation and Spearman’s ρ for the correlation of C-reactive protein (CRP) and fibrinogen with the CLI score and found a highly significant statistical correlation for both parameters (for CRP: Pearson’s ρ = 0.3; Spearman’s ρ = 0.4; for fibrinogen: Pearson’s ρ = 0.2; Spearman’s ρ = 0.3; P value for all calculations <0.001).

**DISCUSSION**

This study demonstrated that the risk for CLI in PAOD patients can be determined easily on the basis of their clinical parameters and concomitant medication. Our score correlates well with inflammatory parameters that reflect the activity of atherosclerosis in these patients.

In general, scoring systems can be useful for identifying patients at high risk for vascular endpoints. The Framingham risk score can be used to highlight patients at high risk for cardiovascular disease and those with a high-risk score might benefit from intensive management of their vascular risk factors, as might those with a high Graz CLI score. We hypothesize that those PAOD patients should be treated immediately as their elevated inflammatory parameters suggest a more aggressive atherosclerosis.

With our score, age and diabetes were among the most aggressive risk factors, with an OR of 2.0 and 3.1, respectively. These findings are in accord with similar findings that our group has published recently. We were able to show that an elevated CHA2DS2-VASc score is associated with an elevated CLI risk. With this scoring system, diabetes and age >75 years were the 2 main entities associated with CLI. Both entities are also closely linked to inflammation, especially in atherosclerotic patients. There are signs of chronic inflammation in both, diabetes and insulin resistance, a typical feature of type 2 diabetes. Inflammation and size of necrotic core are also increased in diabetic patients with CAD. Concerning age there are similar data on age-related inflammation increase in atherosclerotic patients. The reason for this age-related systemic chronic inflammation is mainly attributed to the progressive activation of immune cells over time.

When the Graz CLI score was analyzed, the only protective factor for CLI was concomitant statin medication. Much research has been conducted to evaluate the protective effect of statin therapy, especially in CLI patients. Westin et al recently showed that statins were associated with lower mortality, a reduction in major adverse cardiovascular and cerebrovascular events, and longer amputation-free survival in CLI patients. Even in patients who have undergone endovascular treatment, statin therapy is associated with superior clinical outcome. Especially in combination with angiotensin-converting enzyme inhibition a survival benefit can be demonstrated.

**TABLE 3. Adjusted Risk Factors for Critical Limb Ischemia in Peripheral Arterial Occlusive Disease Patients (Cohort 1)**

| Risk Factor                     | Adjusted OR (95% CI) | P     | CLI Risk Points |
|---------------------------------|----------------------|-------|----------------|
| Type 2 diabetes                 | 3.1 (2.2–4.4)        | <0.001| 2              |
| LMWH therapy                    | 2.8 (1.7–4.4)        | <0.001| 2              |
| Prior myocardial infarction     | 2.5 (1.1–5.5)        | 0.03  | 2              |
| Age ≥ 75 y                      | 2.0 (1.3–3.0)        | <0.001| 2              |
| Cardiac glycosides              | 1.9 (1.3–3.4)        | 0.003 | 1              |
| Age 65–74 y                     | 1.6 (1.1–2.5)        | 0.03  | 1              |
| Loop diuretics                  | 1.5 (1.1–2.1)        | 0.01  | 1              |
| Statin therapy                  | 0.5 (0.4–0.8)        | <0.001| –1             |

CLI = critical limb ischemia, LMWH = low molecular weight heparin, OR = odds ratio.

Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
outcomes, including worsening of symptoms, peripheral use was associated with an 18% lower rate of adverse limb symptoms.18–20

PAOD patients were further underlined in large databases, like the REACH Registry.16 A recent publication on symptomatic PAOD patients revealed that among them, statin therapy should by all means be initiated for all PAOD patients, especially those with diabetes. These recommendations are also reflected in current guidelines, although adherence to them is rather poor.17

One further CLI risk factor in our score was glycoside inhibitors. Statins may have even reduced mortality in diabetic CLI patients during a 2-year follow-up.18–20 The beneficial findings of statins in CLI patients were further underlined in large databases, like the REACH Registry.16 A recent publication on symptomatic PAOD patients revealed that among them, statin use was associated with an 18% lower rate of adverse limb outcomes, including worsening of symptoms, peripheral revascularization, and ischemic amputations.16 Statin therapy should by all means be initiated for all PAOD patients, especially those with diabetes. These recommendations are also reflected in current guidelines, although adherence to them is rather poor.17

One further CLI risk factor in our score was glycoside treatment. As this medication is mainly given to patients with congestive heart failure, their low cardiac output causes hemodynamic alterations that include a low flow state, increased peripheral resistance, endothelial cell dysfunction, and vascular smooth muscle cell dysfunction that could exacerbate ischemic symptoms.18–20

One further factor associated with CLI in our cohort was a history of MI. We already know that patients with PAOD have a higher risk of fatal and nonfatal cardiovascular events than do patients with symptomatic atherosclerosis in other vascular beds such as the coronary, carotid, and cerebral arteries.21,22

The higher values for inflammatory parameters with higher CLI scores might reflect a more active underlying atherosclerosis that in turn could increase their MI rate.

In elderly patients, dehydration often leads to renal impairment and even acute renal failure. Diuretics are often prescribed for the many geriatric patients who suffer from congestive heart failure, and loop diuretics were implicated as a further CLI risk factor in our cohort. Dehydration reduces peripheral perfusion, leading to vascular occlusion and more severe PAOD symptoms, reflected in a higher CLI rate.

Antiplatelet therapy is mandatory for atherosclerosis patients, especially after endovascular treatment, but for some patients, such as those with atrial fibrillation, vitamin K antagonist (VKA) is indicated. When VKA therapy is contraindicated because of a high bleeding risk, LMWH is an alternative. This therapy was a risk factor for CLI in our cohort with an OR of 2.8. One explanation is that these patients might tend to be multimorbid, with highly active underlying atherosclerosis leading to a high CLI rate. There are, however, also data showing that heparins might activate platelets.23 This activation of platelets might explain the increase in vascular endpoints including the development of CLI.

The main drawback of our study is its retrospective design. Furthermore, there were statistically significant differences between cohort 1 and cohort 2 concerning incidence of CAD, atrial fibrillation, and comedication (clopidogrel, angiotensin receptor blocker, and β-blocker therapy). As clopidogrel is beneficial especially in PAD patients,24 at least some impact on our results cannot be excluded.

With the Graz CLI score, we have developed a simple risk stratification scheme on the basis of information that can be easily acquired from the medical history, without any laboratory parameters. This score proved to be a promising tool to identify PAOD patients at high risk for CLI and should be further evaluated in an upcoming prospective study.

ACKNOWLEDGMENT

The authors thank Eugenia Lamont for language editing.

REFERENCES

1. Bertomeu V, Morillas P, Gonzalez-Juanatey JR, et al. Prevalence and prognostic influence of peripheral arterial disease in patients ≥ 40 years old admitted into hospital following an acute coronary event. Eur J Vasc Endovasc Surg. 2008;36:189–196.
2. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg. 2007;45 (suppl S):S5–S67.
3. Novo S, Coppola G, Milio G. Critical limb ischemia: definition and natural history. Current drug targets. Cardiovasc Haematol Disord. 2004;4:219–225.
4. Bertele V, Roncaglioni MC, Pangrazzi J, et al. Clinical outcome and its predictors in 1560 patients with critical leg ischaemia. Chronic Critical Leg Ischaemia Group. Eur J Vasc Endovasc Surg. 1999;18:401–410.
5. D’Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117:743–753.
6. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation. 2002;105:310–315.
7. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease.
(lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation.  

J Am Coll Cardiol. 2006;47:1239–1312.

8. Gary T, Belaj K, Hafner F, et al. A high CHA(2)DS(2)-VASc score is associated with a high risk for critical limb ischemia in peripheral arterial occlusive disease patients. Atherosclerosis. 2012;225:517–520.

9. Cruz NG, Sousa LP, Sousa MO, et al. The linkage between inflammation and Type 2 diabetes mellitus. Diabetes Res Clin Pract. 2013;99:85–92.

10. Purushothaman KR, Purushothaman M, Muntner P, et al. Inflammation, neovascularization and intra-plaque hemorrhage are associated with increased reparative collagen content: implication for plaque progression in diabetic atherosclerosis. Vasc Med. 2011;16:103–108.

11. Burke AP, Kolodgie FD, Zieske A, et al. Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study. Arterioscler Thromb Vasc Biol. 2004;24:1266–1271.

12. Plowden J, Renshaw-Hoelscher M, Engleman C, et al. In innate immunity in aging: impact on macrophage function. Aging Cell. 2004;3:161–167.

13. Westin GG, Armstrong EJ, Bang H, et al. Association between statin medications and mortality, major adverse cardiovascular event, and amputation-free survival in patients with critical limb ischemia. J Am Coll Cardiol. 2014;63:682–690.

14. Asello FA, Khan AA, Meltzer AJ, et al. Statin therapy is associated with superior clinical outcomes after endovascular treatment of critical limb ischemia. J Vasc Surg. 2012;55:371–379. discussion 380.

15. Faglia E, Clerici G, Scatena A, et al. Effectiveness of combined therapy with angiotensin-converting enzyme inhibitors and statins in reducing mortality in diabetic patients with critical limb ischemia: an observational study. Diabetes Res Clin Pract. 2014;103:292–297.

16. Kumbhani DJ, Steg PG, Cannon CP, et al. Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. Eur Heart J. 2014;35:2864–2872.

17. Armstrong EJ, Chen DC, Westin GG, et al. Adherence to guideline-recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease. J Am Heart Assoc. 2014;3:e000697. doi: 10.1161/JAHA.113.000697.

18. Kubo SH, Rector TS, Bank AJ, et al. Endothelium-dependent vasodilation is attenuated in patients with heart failure. Circulation. 1991;84:1589–1596.

19. Ledoux J, Gee DM, Leblanc N. Increased peripheral resistance in heart failure: new evidence suggests an alteration in vascular smooth muscle function. Br J Pharmacol. 2003;139:1245–1248.

20. Drexler H, Hayoz D, Munzel T, et al. Endothelial function in chronic congestive heart failure. Am J Cardiol. 1992;69:1596–1601.

21. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg. 2007;33 (suppl 1):S1–S75.

22. Norgren L, Hiatt WR, Dormandy JA, et al. The next 10 years in the management of peripheral artery disease: perspectives from the ‘PAD 2009’ Conference. Eur J Vasc Endovasc Surg. 2010;40:375–380.

23. Xiao Z, Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation. 1998;97:251–256.

24. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348:1329–1339.